These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 7738644

  • 1. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody.
    Breitz HB, Durham JS, Fisher DR, Weiden PL, DeNardo GL, Goodgold HM, Nelp WB.
    J Nucl Med; 1995 May; 36(5):754-61. PubMed ID: 7738644
    [Abstract] [Full Text] [Related]

  • 2. Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results.
    Breitz HB, Durham JS, Fisher DR, Weiden PL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5817s-5822s. PubMed ID: 7493352
    [Abstract] [Full Text] [Related]

  • 3. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Breitz HB, Wendt RE, Stabin MS, Shen S, Erwin WD, Rajendran JG, Eary JF, Durack L, Delpassand E, Martin W, Meredith RF.
    J Nucl Med; 2006 Mar 01; 47(3):534-42. PubMed ID: 16513624
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 01; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 01; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 6. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.
    Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J, Weiden P.
    Obstet Gynecol; 1993 Oct 01; 82(4 Pt 1):586-93. PubMed ID: 8377986
    [Abstract] [Full Text] [Related]

  • 7. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R.
    J Nucl Med; 2009 Jul 01; 50(7):1153-60. PubMed ID: 19525452
    [Abstract] [Full Text] [Related]

  • 8. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct 01; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 9. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC.
    J Nucl Med; 2004 Jul 01; 45(7):1224-32. PubMed ID: 15235070
    [Abstract] [Full Text] [Related]

  • 10. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.
    J Nucl Med; 2000 Dec 01; 41(12):1999-2010. PubMed ID: 11138685
    [Abstract] [Full Text] [Related]

  • 11. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N, Torres LA, Morales A, Ramos M, Alvarez I, Pérez N, Fraxedas R, Rodríguez O, Rodríguez N, Pérez R, Lage A, Stabin MG.
    J Nucl Med; 1998 Jan 01; 39(1):15-23. PubMed ID: 9443731
    [Abstract] [Full Text] [Related]

  • 12. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
    Breitz HB, Fisher DR, Wessels BW.
    J Nucl Med; 1998 Oct 01; 39(10):1746-51. PubMed ID: 9776281
    [Abstract] [Full Text] [Related]

  • 13. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG, Sgouros G, American Association of Physicists in Medicine.
    J Nucl Med; 2004 Oct 01; 45(10):1725-33. PubMed ID: 15471841
    [Abstract] [Full Text] [Related]

  • 14. Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol.
    Zanzonico PB, Divgi C.
    Semin Nucl Med; 2008 Mar 01; 38(2):S30-9. PubMed ID: 18243841
    [Abstract] [Full Text] [Related]

  • 15. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
    Breitz HB, Weiden PL, Vanderheyden JL, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC.
    J Nucl Med; 1992 Jun 01; 33(6):1099-109. PubMed ID: 1597723
    [Abstract] [Full Text] [Related]

  • 16. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 17. Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart.
    Kinuya S, Yokoyama K, Izumo M, Sorita T, Obata T, Mori H, Shiba K, Watanabe N, Shuke N, Michigishi T, Tonami N.
    Cancer Lett; 2005 Feb 28; 219(1):41-8. PubMed ID: 15694663
    [Abstract] [Full Text] [Related]

  • 18. Biodistribution and dosimetry of indium-111-polyclonal IgG in normal subjects.
    Datz FL, Castronovo FP, Christian PE, Anderson CE, Crebs K, Morton KA, Rauh DA.
    J Nucl Med; 1995 Dec 28; 36(12):2372-9. PubMed ID: 8523134
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G.
    Clin Cancer Res; 1995 Dec 28; 1(12):1447-54. PubMed ID: 9815943
    [Abstract] [Full Text] [Related]

  • 20. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
    Stewart JS, Hird V, Snook D, Sullivan M, Myers MJ, Epenetos AA.
    Int J Cancer Suppl; 1988 Dec 28; 3():71-6. PubMed ID: 3209303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.